ABSTRACT
The outbreak of coronavirus disease 2019（COVID-19）, caused by severe acute respiratory syndrome coronavirus（SARS-CoV-2） at the end of 2019, results in a global rapid pandemic.The emerging infectious disease is life threaten and profoundly undermines the normal operation all over the world.Rapid and accurate detection of SARS-CoV-2 is an essential component of efforts to combat SARS-CoV-2 spread.Although many technologies for SARS-CoV-2 detection have been commercialized and have played a role in the control of COVID-19 epidemic to some extent yet, each of them is still with certain limitations.Recently, increasing number of teams attempt to detect SARS-CoV-2 by CRISPR-Cas（clustered regularly interspaced short palindromic repeats-Cas） system.With excellent specificity and sensitivity, it has been believed to be a potential technology in COVID-19 diagnosis and therapy.The review provides an overview of CRISPR-Cas system for SARS-CoV-2 detection and COVID-19 therapy, along with its clinical translation potential.Hope it has some referential significance for the control of SARS-CoV-2 spread and COVID-19 epidemic.
ABSTRACT
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has led to more than 150 million infections and about 3.1 million deaths up to date. Currently, drugs screened are urgently aiming to block the infection of SARS-CoV-2. Here, we explored the interaction networks of kinase and COVID-19 crosstalk, and identified phosphoinositide 3-kinase (PI3K)/AKT pathway as the most important kinase signal pathway involving COVID-19. Further, we found a PI3K/AKT signal pathway inhibitor capivasertib restricted the entry of SARS-CoV-2 into cells under non-cytotoxic concentrations. Lastly, the signal axis PI3K/AKT/FYVE finger-containing phosphoinositide kinase (PIKfyve)/PtdIns(3,5)P2 was revealed to play a key role during the cellular entry of viruses including SARS-CoV-2, possibly providing potential antiviral targets. Altogether, our study suggests that the PI3K/AKT kinase inhibitor drugs may be a promising anti-SARS-CoV-2 strategy for clinical application, especially for managing cancer patients with COVID-19 in the pandemic era.